M&A Deals Of Indian Drug Makers Heat Up In 2008
This article was originally published in PharmAsia News
Executive Summary
Indian drug makers stepped up their merger and acquisition moves in April, eclipsing the value of similar deals in the first three months of this year. Eight acquisitions in the first three months of this year were valued at $152 million, but just two of the six April deals were valued at more than $473 million. The financial amounts of some of the deals have not been disclosed, including those of Dr. Reddy's Laboratories' leading acquisition activity over the four month period. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.